IPN.PA Ipsen S.A. (EURONEXT) up 11.46% on 13 Feb 2026: guidance lifts outlook

IPN.PA stock climbed 11.46% to €154.70 at market close on 13 Feb 2026 after Ipsen S.A. reported strong 2025 results and issued FY 2026 guidance above expectations. Trading volume jumped to 146,747 shares, roughly 2.50x the average, as investors priced in faster portfolio growth and Somatuline supply dynamics. We examine the drivers, valuation, technicals and model forecasts that explain today’s top-gainer move on EURONEXT in the Europe healthcare patch.

IPN.PA stock: today’s price action and market context

Ipsen S.A. (IPN.PA) finished the session at €154.70, up €15.90 or 11.46% from the previous close of €138.80. The intraday range was €146.90–€154.70, and the stock set a new 52-week high above the prior €152.50 level. Volume of 146,747 versus average 90,898 shows institutional attention and higher liquidity today.

The move placed IPN.PA among top gainers on EURONEXT as healthcare trading outperformed the wider market. Relative to the sector average PE of 31.03, Ipsen’s reported PE of 27.49 looks modest, supporting multiple expansion on positive guidance.

IPN.PA stock: drivers — 2025 results, 2026 guidance and pipeline

Ipsen’s FY 2025 report showed sales growth of 8.10% (reported) with core operating income of €1,294.00m and a core margin at 35.20%. Management issued 2026 guidance of total sales growth greater than 13.00% at constant currency and core operating margin above 35.00%, a clear catalyst for the rally. source

Pipeline milestones and the ImCheck acquisition (IPN60340/ICT01) plus IPN10200 aesthetics data and regulatory readouts supported sentiment. Investors also noted generic lanreotide production challenges that may buoy Somatuline sales in 2026. source

IPN.PA stock: fundamentals, cash flow and valuation

Key fundamentals show EPS €5.37, PE 27.49, and market cap roughly €12.21bn. Ipsen’s price vs moving averages is constructive: 50-day average €127.78 and 200-day average €116.16, both well below today’s price. The company reports free cash flow per share of €9.76 and a dividend per share of €1.40 (yield ~0.95%).

Balance-sheet metrics are healthy: debt-to-equity 0.23, net debt to EBITDA negative (net cash position), and interest coverage 29.37, supporting continued R&D investment and external deals while limiting financial risk.

IPN.PA stock: Meyka AI grade and technical view

Meyka AI rates IPN.PA with a score out of 100: 77.61 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Technically, RSI 50.90 and ADX 32.00 show a strengthening trend with ATR 2.33. On-balance volume and a 2.50x relative volume confirm conviction. Short-term momentum is positive but MACD histogram remains modest, so pullbacks could offer tactical entries.

IPN.PA stock: forecasts, price targets and implied moves

Meyka AI’s forecast model projects monthly €123.11, quarterly €126.94, and yearly €118.68 targets. Compared with the current price €154.70, the model implies a near-term downside to the yearly forecast of -23.29%, a -17.75% gap to the 3-year forecast (€127.25), and a small -3.34% gap to the 7-year projection (€149.68). Forecasts are model-based projections and not guarantees.

Analysts and company guidance suggest upside to revenue and margins in 2026. A sensible trading plan balances the near-term upside priced by markets against the model’s reversion scenarios.

IPN.PA stock: risks, catalysts and next events

Key catalysts: five 2026 regulatory/clinical milestones, full data readouts for IPN10200, and Q1 2026 sales on 23 April 2026. Positive trial or regulatory outcomes could sustain multiple expansion.

Primary risks include clinical setbacks (past FALKON outcome for fidrisertib), competition from generics affecting Somatuline long-term, and currency headwinds (management cites ~-2% FX headwind). Monitor headline trial readouts and business-development activity closely.

Final Thoughts

IPN.PA stock led EURONEXT gainers on 13 Feb 2026 after Ipsen’s strong FY 2025 results and above-consensus 2026 guidance. The move to €154.70 reflected higher-than-normal volume (146,747) and renewed investor focus on Somatuline, Iqirvo, IPN10200 and recent business development such as ImCheck. Fundamentals remain solid: EPS €5.37, PE 27.49, strong free cash flow and a clean balance sheet with debt-to-equity 0.23. Meyka AI’s forecast model projects a one-year figure of €118.68, implying -23.29% versus today’s price, while longer-term projections narrow the gap to near parity by year seven. Our Meyka grade (B+, 77.61 /100) reflects the mix of strong operational execution and pipeline upside balanced against clinical and generic risks. Traders should watch the five 2026 milestones and the Q1 sales release on 23 April 2026 for confirmation. Remember, forecasts are model-based projections and not guarantees, and this analysis is informational, not investment advice. Meyka AI-powered market analysis platform provides these data-driven insights to help form your view.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.